Abstract
Objective: Determine if donepezil will raise the insulin-like growth factor-1 levels of patients with amnestic mild cognitive impairment and Alzheimer's disease.
Design: In an outpatient setting, recruit amnestic mild cognitive impairment and Alzheimer's disease patients who were to start treatment with donepezil. Measure total serum insulin-like growth factor-1 levels before and after 3-6 months of treatment.
Results: Twenty-four patients were recruited. After a mean duration of 129 ± 37 days, 14 patients returned taking 5 mg (n=4) or 10 mg (n=10) donepezil per day. Twelve patients experienced decreases in their insulin-like growth factor-1 levels, one had no change, and one experienced an increase. Their mean insulin-like growth factor-1 level dropped by 13%, from 113 ± 31 ng/ml to 98 ± 28 ng/ml (p<0.001).
Conclusion: Contrary to the expected increase in insulin-like growth factor-1 levels in response to donepezil that has been reported for normal elderly adults, our patients experienced decreases. This finding suggests that the somatotropic axis is altered in amnestic mild cognitive impairment and Alzheimer's disease relative to normal older adults.
Keywords: Acetylcholinesterase inhibitor, Alzheimer's disease, donepezil, insulin-like growth factor-1, mild cognitive impairment, somatotropic growth hormone/insulin-like growth factor-1 axis.
CNS & Neurological Disorders - Drug Targets
Title:Donepezil May Reduce Insulin-Like Growth Factor-1 (IGF-1) Levels in Alzheimer’s disease
Volume: 15 Issue: 1
Author(s): Tom Ala
Affiliation:
Keywords: Acetylcholinesterase inhibitor, Alzheimer's disease, donepezil, insulin-like growth factor-1, mild cognitive impairment, somatotropic growth hormone/insulin-like growth factor-1 axis.
Abstract: Objective: Determine if donepezil will raise the insulin-like growth factor-1 levels of patients with amnestic mild cognitive impairment and Alzheimer's disease.
Design: In an outpatient setting, recruit amnestic mild cognitive impairment and Alzheimer's disease patients who were to start treatment with donepezil. Measure total serum insulin-like growth factor-1 levels before and after 3-6 months of treatment.
Results: Twenty-four patients were recruited. After a mean duration of 129 ± 37 days, 14 patients returned taking 5 mg (n=4) or 10 mg (n=10) donepezil per day. Twelve patients experienced decreases in their insulin-like growth factor-1 levels, one had no change, and one experienced an increase. Their mean insulin-like growth factor-1 level dropped by 13%, from 113 ± 31 ng/ml to 98 ± 28 ng/ml (p<0.001).
Conclusion: Contrary to the expected increase in insulin-like growth factor-1 levels in response to donepezil that has been reported for normal elderly adults, our patients experienced decreases. This finding suggests that the somatotropic axis is altered in amnestic mild cognitive impairment and Alzheimer's disease relative to normal older adults.
Export Options
About this article
Cite this article as:
Ala Tom, Donepezil May Reduce Insulin-Like Growth Factor-1 (IGF-1) Levels in Alzheimer’s disease, CNS & Neurological Disorders - Drug Targets 2016; 15 (1) . https://dx.doi.org/10.2174/1871527315666151110124240
DOI https://dx.doi.org/10.2174/1871527315666151110124240 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drug Treatment of Metabolic Syndrome
Current Clinical Pharmacology Pharmacokinetic-Pharmacodynamic Modeling of Antihypertensive Drugs: From Basic Research to Clinical Practice
Current Hypertension Reviews Targeting Vascular Redox Biology Through Antioxidant Gene Delivery: A Historical View and Current Perspectives
Recent Patents on Cardiovascular Drug Discovery Highlights on Important Medicinal Plants for the Menopause Syndrome
Current Women`s Health Reviews Anesthetic Pharmacology and Perioperative Considerations for Heart Transplantation
Current Clinical Pharmacology The NOX1/4 Inhibitor GKT136901 as Selective and Direct Scavenger of Peroxynitrite
Current Medicinal Chemistry Relationships Between Alcohol Consumption, Smoking Status and Food Habits in Greek Adolescents. Vascular Implications for the Future
Current Vascular Pharmacology Taking Risk Prediction to the Next Level. Advances in Biomarker Research for Atherosclerosis
Current Pharmaceutical Design Novel Molecular Targets in the Treatment of Cardiac Hypertrophy
Recent Patents on Cardiovascular Drug Discovery Gene-Gene and Gene-Clinical Factors Interaction in Acute Myocardial Infarction: A New Detailed Risk Chart
Current Pharmaceutical Design PDE5 Inhibitors in the Treatment of LUTS
Current Pharmaceutical Design Actions of Rho-Kinase Inhibitors in Cardiovascular Diseases
Current Enzyme Inhibition Comparative Study of Nutritional and Phytochemical Attributes of Andrographis paniculata, Bryophyllum pinnatum and Clitoria ternatea for Nutraceutical Applications
Current Nutrition & Food Science Anti-VEGF Drugs in Eye Diseases: Local Therapy with Potential Systemic Effects
Current Pharmaceutical Design Mediterranean Diet and Hypertension; From the Clinical and Epidemiologic Evidences to Prevention
Current Hypertension Reviews Phosphonic Esters and their Application of Protease Control
Current Pharmaceutical Design Editorial [Hot topic: Childhood Asthma - The State of Play in 2010 (Guest Editor: Steve Turner)]
Current Pediatric Reviews Differential ERK1/2 Signaling and Hypertrophic Response to Endothelin-1 in Cardiomyocytes from SHR and Wistar-Kyoto Rats: A Potential Target for Combination Therapy of Hypertension
Current Vascular Pharmacology Humoral and Mechanical Cross-Talk in the Vasculature: Perspectives in Vascular Disease
Vascular Disease Prevention (Discontinued) Active Metabolites Resulting from Decarboxylation, Reduction and Ester Hydrolysis of Parent Drugs
Current Drug Metabolism